{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:11:34Z","timestamp":1783012294667,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.yebeh.2023.109566","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T05:13:48Z","timestamp":1702098828000},"page":"109566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Predictors and associated factors with adverse drug reaction in people with epilepsy"],"prefix":"10.1016","volume":"150","author":[{"given":"Luqman","family":"Ogunjimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinyinka","family":"Alabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderonke","family":"Aderinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabisi","family":"Ogunjimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Oladunjoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeola","family":"Kasali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kasumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibironke","family":"Oyenuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shittabey","family":"Akinbodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupeoluwa","family":"Onipede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oludolapo","family":"Dele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Adeyemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele","family":"Osalusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109566_b0005","first-page":"132","article-title":"Antiepileptic drugs","volume":"22","author":"Abou-Khalil","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.yebeh.2023.109566_b0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nmt-2017-0044","article-title":"Medication adherence and adverse effect profile of antiepileptic drugs in Nigerian patients with epilepsy","volume":"8","author":"Fadare","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.yebeh.2023.109566_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2014.07.009","article-title":"Antiepileptic drugs and quality of life in patients with epilepsy: A tertiary care hospital-based study","volume":"6","author":"George","year":"2015","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.yebeh.2023.109566_b0020","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2023.109566_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/cer-2016-0057","article-title":"Adverse effects of carbamazepine monotherapy among patients in Nigeria: a pilot study and implications","volume":"6","author":"Olusanya","year":"2017","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.yebeh.2023.109566_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ane.12096","article-title":"Epilepsy treatment gap: prevalence and associated factors in Southeast Nigeria","volume":"128","author":"Nwani","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2023.109566_b0035","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/bcp.14577","article-title":"Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality","volume":"87","author":"Adedapo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109566_b0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.yebeh.2023.109566_b0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/1756-0500-6-473","article-title":"Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital","volume":"6","author":"Habib","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.yebeh.2023.109566_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-019-0285-y","article-title":"Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015","volume":"20","author":"Du","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.yebeh.2023.109566_b0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574886314666190311112710","article-title":"Adverse drug reactions of anti-epileptic drugs in children with epilepsy: A cross-sectional study","volume":"14","author":"Kaushik","year":"2019","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2023.109566_b0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109566_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.seizure.2014.01.003","article-title":"Validation of Chinese version of the Morisky medication adherence scale in patients with epilepsy","volume":"23","author":"Yang","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109566_b0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.yebeh.2009.04.026","article-title":"Antiepileptic drug use in women of childbearing age","volume":"15","author":"Meador","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109566_b0075","doi-asserted-by":"crossref","unstructured":"St. Louis E. Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care. Curr Neuropharmacol 2009;7:106\u201314. https:\/\/doi.org\/10.2174\/157015909788848857.","DOI":"10.2174\/157015909788848857"},{"key":"10.1016\/j.yebeh.2023.109566_b0080","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.seizure.2014.06.007","article-title":"Predictors of quality of life and their interrelations in Korean people with epilepsy: a MEPSY study","volume":"23","author":"Lee","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109566_b0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/epd.2018.0957","article-title":"The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know?","volume":"20","author":"Brodie","year":"2018","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2023.109566_b0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.yebeh.2017.03.022","article-title":"An overview of the 2017 ILAE operational classification of seizure types","volume":"70","author":"Fisher","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109566_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNP.0b013e3182784729","article-title":"American Clinical Neurophysiology Society\u2019s Standardized Critical Care EEG Terminology: 2012 version","volume":"30","author":"Hirsch","year":"2013","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2023.109566_b0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109566_b0105","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmjqs-2013-002658","article-title":"Adverse drug events and medication errors in Japanese paediatric inpatients: a retrospective cohort study","volume":"23","author":"Sakuma","year":"2014","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.yebeh.2023.109566_b0110","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.02.020405","article-title":"An estimate of the prevalence of epilepsy in Sub-Saharan Africa: A systematic analysis","volume":"2","author":"Paul","year":"2012","journal-title":"J Glob Health"},{"key":"10.1016\/j.yebeh.2023.109566_b0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 2","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.yebeh.2023.109566_b0120","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1039\/C6CC00959J","article-title":"Polymorphism in phenobarbital: discovery of a new polymorph and crystal structure of elusive form V","volume":"52","author":"Roy","year":"2016","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.yebeh.2023.109566_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group","volume":"274","author":"Bates","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2023.109566_b0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eplepsyres.2008.08.008","article-title":"Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study","volume":"82","author":"Belcastro","year":"2008","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109566_b0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","article-title":"Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy","volume":"145","author":"Joshi","year":"2017","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.yebeh.2023.109566_b0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/epi4.12325","article-title":"Clinical and etiological characteristics of epilepsy in people from Niger: a hospital-based study from a tertiary care referral center of Niamey","volume":"4","author":"Assadeck","year":"2019","journal-title":"Niger Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109566_b0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2023.109566_b0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs\u2013rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109566_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.13246","article-title":"Epilepsy treatment gap in Sub-Saharan Africa: Meta-analysis of community-based studies","volume":"142","author":"Owolabi","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2023.109566_b0160","doi-asserted-by":"crossref","first-page":"e100724","DOI":"10.1371\/journal.pone.0100724","article-title":"An estimate of the incidence and prevalence of stroke in Africa: a systematic review and meta-analysis","volume":"9","author":"Adeloye","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2023.109566_b0170","article-title":"Adverse drug reaction in people with epilpsy","author":"Ogunjimi","year":"2023","journal-title":"Preprints"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023004857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023004857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:15:47Z","timestamp":1736428547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023004857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"alternative-id":["S1525505023004857"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109566","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors and associated factors with adverse drug reaction in people with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109566"}}